Blackstone Life Sciences, a division of Blackstone Inc. (BX), Monday announced a research and development funding agreement with Johnson & Johnson (JNJ) to advance the clinical development of bleximenib for the treatment of acute myeloid leukemia.
Under this agreement, bleximenib's promising clinical data along with Johnson & Johnson's deep expertise in hematologic malignancies is expected to create a strong foundation to address critical gaps in patient care.
Meanwhile, Johnson & Johnson and funds managed by the company will jointly finance a portion of the ongoing and future clinical trials of bleximenib.
In the pre-market hours, BX is trading at $120.25, down 0.85 percent, and JNJ is trading at $242.52 on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.